Signpath Pharma, Inc. (SGTH) financial statements (2022 and earlier)
Company profile
| Business Address |
3477 CORPORATE PARKWAY, SUITE 100 CENTER VALLEY, PA 18034 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 692 | 716 | 1,241 | 32 | ||
| Cash and cash equivalents | 692 | 716 | 1,241 | 32 | ||
| Prepaid expense | 5 | ✕ | ||||
| Total current assets: | 698 | 716 | 1,241 | 32 | ||
| Noncurrent Assets | ||||||
| Property, plant and equipment | 5 | 0 | ||||
| Other undisclosed noncurrent assets | (5) | |||||
| Total noncurrent assets: | 0 | |||||
| TOTAL ASSETS: | 698 | 716 | 1,241 | 32 | ||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 310 | 448 | 422 | 894 | ||
| Accrued liabilities | 86 | 75 | ||||
| Interest and dividends payable | 1,730 | |||||
| Other undisclosed accounts payable and accrued liabilities | (1,506) | 373 | 422 | 894 | ||
| Derivative instruments and hedges, liabilities | 5,687 | |||||
| Other undisclosed current liabilities | 862 | |||||
| Total current liabilities: | 310 | 448 | 422 | 7,444 | ||
| Noncurrent Liabilities | ||||||
| Total liabilities: | 310 | 448 | 422 | 7,444 | ||
| Stockholders' equity | ||||||
| Stockholders' equity attributable to parent, including: | 388 | 268 | 820 | (7,412) | ||
| Preferred stock | 1 | 1 | ||||
| Common stock | 14 | 14 | 13 | 13 | ||
| Common stock, share subscribed but unissued, subscriptions receivable | (249) | |||||
| Additional paid in capital | 13,944 | 12,700 | 10,120 | 1,287 | ||
| Accumulated deficit | (15,052) | (13,417) | ||||
| Warrants and rights outstanding | 15,699 | 15,849 | 10,614 | |||
| Other undisclosed stockholders' equity attributable to parent | 1,731 | (14,729) | (25,164) | (19,325) | ||
| Total stockholders' equity: | 388 | 268 | 820 | (7,412) | ||
| TOTAL LIABILITIES AND EQUITY: | 698 | 716 | 1,241 | 32 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|
| Revenues (Other Income) | 24 | ||||
| Gross profit: | 24 | ||||
| Operating expenses | (1,647) | (2,742) | (1,954) | (1,312) | |
| Other undisclosed operating loss | (24) | ||||
| Operating loss: | (1,647) | (2,742) | (1,954) | (1,312) | |
| Nonoperating income (expense) | 12 | (5) | (2) | 1 | |
| Investment income, nonoperating | 1 | 1 | |||
| Other nonoperating income (expense) | 12 | (6) | (3) | 1 | |
| Loss from continuing operations before equity method investments, income taxes: | (1,635) | (2,748) | (1,956) | (1,311) | |
| Other undisclosed income (loss) from continuing operations before income taxes | (1) | (1) | 0 | ||
| Net loss attributable to parent: | (1,635) | (2,748) | (1,957) | (1,311) | |
| Other undisclosed net loss available to common stockholders, basic | (761) | ||||
| Net loss available to common stockholders, diluted: | (2,396) | (2,748) | (1,957) | (1,311) | |
Comprehensive Income ($ in thousands)
| 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|
| Net loss: | (1,635) | (2,748) | (1,957) | (1,311) | |
| Comprehensive loss, net of tax, attributable to parent: | (1,635) | (2,748) | (1,957) | (1,311) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.